The Sooner, the Better

Abstract

Editorialsto be a predictor of use of TH. Thus, the study compels us to ask this very important question-"Why are we not using TH for IHCA?" More importantly, we need to ask who is making the decision. Given our lack of a good tool to choose the ideal candidate for TH and given the evidence we already have, why not offer TH to VTATF-induced IHCA? And while we wait for the elusive "evidence of efficacy and effectiveness" of TH for IHCA in general, how about including our patients in the decision making? We may not know exactly how great the benefit (or harm) of our intervention is, but at least, we would know that our patients want it ( 14).A ray of hope may be shining with the authors* finding that the rate of TH use is increasing over time from less than 1% on 2003 to a little over 3% in 2009. Definitely small but definitely a step in the right direction. Maybe we do not need to wait 17 years (15) before we finally do what is right for (some of) our patients. Are we finally breaking the ice of therapeutic nihilism?